Aggravation Effect of Isoflurane on Aβ25–35-Induced Apoptosis and Tau Hyperphosphorylation in PC12 Cells

Some anesthetics have been suggested to induce Alzheimer??s disease (AD) neuro-pathogenesis. Increasing evidence indicates that hyperphosphorylated tau plays a key role in the pathogenic events that occur in AD. Isoflurane has been shown to induce apoptosis, which leads to accumulation of amyloid-?? (A??). We set out to investigate whether isoflurane can induce apoptosis by increasing hyperphosphorylated tau in A??_25?C35-induced cells and the underlying mechanism. Cultured rat pheochromocytoma cells (PC12) were exposed to 20?mM A??_25?C35 alone or with 2?% isoflurane for 6?h. The cell viability was determined by MTT assay, and the apoptosis rate was detected by flowcytometry. Western blotting and immunocytochemical staining were performed to observe the protein expression of Bcl-2 family, tau phosphorylation of different sites, tau protein kinases and phosphatases. Additionally, lithium chloride was administered to all above groups to investigate the changes of apoptosis rate and protein expression. The apoptosis rate was significantly increased in A??_25?C35 group compared with the others groups, which was accompanied by bcl-2 decline, and the phosphorylation of glycogen synthase kinase-3??(GSK-3??) and tau of two sites increased. LiCl attenuated the cellular apoptosis by inhibition the level of tau phosphorylation. Isoflurane upregulated the level of phosphorylated GSK-3??, which phosphorylate tau at different sites, and aggravated the apoptotic rate of the A??_25?C35-induced PC12 cells. It indicated that isoflurane-induced tau phosphorylation might play a role in the AD-like development.     

AMPK regulates homeostasis of invasion and viability in trophoblasts by redirecting glucose metabolism: Implications for pre‐eclampsia

Pre‐eclampsia (PE) is deemed an ischemia‐induced metabolic disorder of the placenta due to defective invasion of trophoblasts during placentation; thus, the driving role of metabolism in PE pathogenesis is largely ignored. Since trophoblasts undergo substantial glycolysis, this study aimed to investigate its function and regulatory mechanism by AMPK in PE development. Metabolomics analysis of PE placentas was performed by gas chromatography–mass spectrometry (GC–MS). Trophoblast‐specific AMPKα1‐deficient mouse placentas were generated to assess morphology. A mouse PE model was established by Reduced Uterine Perfusion Pressure, and placental AMPK was modulated by nanoparticle‐delivered A769662. Trophoblast glucose uptake was measured by 2‐NBDG and 2‐deoxy‐d‐[³H] glucose uptake assays. Cellular metabolism was investigated by the Seahorse assay and GC–MS.PE complicated trophoblasts are associated with AMPK hyperactivation due not to energy deficiency. Thereafter, AMPK activation during placentation exacerbated PE manifestations but alleviated cell death in the placenta. AMPK activation in trophoblasts contributed to GLUT3 translocation and subsequent glucose metabolism, which were redirected into gluconeogenesis, resulting in deposition of glycogen and accumulation of phosphoenolpyruvate; the latter enhanced viability but compromised trophoblast invasion. However, ablation of AMPK in the mouse placenta resulted in decreased glycogen deposition and structural malformation. These data reveal a novel homeostasis between invasiveness and viability in trophoblasts, which is mechanistically relevant for switching between the ‘go’ and ‘grow’ cellular programs.

Pre‐eclampsia (PE) is associated with trophoblast AMPK hyperactivation, presumably due to LKB1 phosphorylation, and glucose uptake is consequently increased via trafficking of GLUT3 from the cytosol to the plasma membrane. Such translocation enhances glycolytic flux and redirects glucose metabolic intermediates into gluconeogenesis, resulting in PEP accumulation, which not only benefits cell survival but also suppresses invasion by repressing MMPs, and thus in turn modulates switching between the ‘go’ and ‘grow’ cellular programs.     

Overexpression of polo-like kinase 1 and its clinical significance in human non-small cell lung cancer

Polo-like kinase 1 is a serine/threonine kinase which plays an essential role in mitosis and malignant transformation. The aim of this study was to investigate the prognostic significance of polo-like kinase 1 expression and determine its possibility as a therapeutic target in non-small cell lung cancer. Semi-quantitative RT-PCR assay was performed to detect polo-like kinase 1 mRNA expression in non-small cell lung cancer cells or tissues. Immunohistochemistry was performed to detect polo-like kinase 1 protein expression in 100 non-small cell lung cancer tissue samples, and the associations of polo-like kinase 1 expression with clinicopathological factors or prognosis of non-small cell lung cancer patients were evaluated. RNA interference was employed to inhibit endogenous polo-like kinase 1 expression and analyzed the effects of polo-like kinase 1 inhibition on the malignant phenotypes of non-small cell lung cancer cells including growth, apoptosis, radio- or chemoresistance. Also, the possible molecular mechanisms were also investigated. The levels of polo-like kinase 1 mRNA expression in non-small cell lung cancer cell lines or tissues were significantly higher than those in normal human bronchial epithelial cell line or corresponding non-tumor tissues. High polo-like kinase 1 expression was significantly correlated with advanced clinical stage, higher tumor classification and lymph node metastasis of non-small cell lung cancer patients (P = 0.001, 0.004 and 0.001, respectively). Meanwhile, high polo-like kinase 1 protein expression was also an independent prognostic molecular marker for non-small cell lung cancer patients (hazard ratio: 2.113; 95% confidence interval: 1.326-3.557; P = 0.017). Polo-like kinase 1 inhibition could significantly inhibit in vitro and in vivo proliferation, induce cell arrest of G₂/M phase and apoptosis enhancement in non-small cell lung cancer cells, which might be activation of the p53 pathway and the Cdc25C/cdc2/cyclin B1 feedback loop. Further, inhibition of polo-like kinase 1 could enhance the sensitivity of non-small cell lung cancer cells to taxanes or irradiation. Thus, polo-like kinase 1 might be a prognostic marker and a chemo- or radiotherapeutic target for non-small cell lung cancer.     

大连市一起由境外输入引起的本土新冠肺炎关联病例的病毒基因组特征分析

了解引起大连市本土新型冠状病毒肺炎（COVID-19）的新型冠状病毒（SARS-CoV-2）流行株的基因组特征和变异情况,追溯SARS-CoV-2来源。

选取2022年8月20日—9月14日97例由境外输入引起的COVID-19关联病例的样本。采用SARS-CoV-2全基因组靶向扩增结合高通量测序技术（Ion Torrent测序平台）进行全基因组测序。分析SARS-CoV-2的基因组特征、核苷酸和氨基酸突变位点和基因分型。构建进化树,结合病例的流行病学资料,溯源SARS-CoV-2流行株。

共获得97例SARS-CoV-2全基因组序列,基因组全长29 735～29 741 bp,平均测序深度1 457×～50 485×,测序覆盖率范围95.9%～100.0%。同NCBI数据库中的SARS-CoV-2参考基因组（NC_045512）序列相比,97例SARS-CoV-2全基因组序列共享75个核苷酸突变位点,22例在此基础上新增1～3个突变位点。75个共享突变位点类型包括：4个非编码区和7个基因编码区,其中基因编码区的70个突变位点,来自基因ORF1ab、S、ORF3a、E、M、ORF8、N。共享的氨基酸突变类型包括15个同义突变和51个非同义突变。97例SARS-CoV-2全基因组序列,Pangolin分型为BA.5.2.1.21 （BF.21进化分支）型,Nextstrain分型为22B型,GISAID分型为GRA型。经与大连SARS-CoV-2基因库的序列比对,与8月9日境外输入的编号20220809-1和20220809-2病例共享75个核苷酸突变位点,高度同源。进化分析结果显示,此次SARS-CoV-2流行株与同时期日本大阪SARS-CoV-2流行株共同处于BF.21进化分支上,与病例20220809-1和20220809-2流行病学调查中的来源国日本一致。

此次SARS-CoV-2流行株属于Omicron变异株（BF.21进化分支）,来源于日本。

     

中国二种盗蛛的分类研究(蜘蛛目:盗蛛科)

本文对我国两种盗蛛：马蹄潮蛛Hygropoda hippocrepiforma Wang,1993和带形盗蛛Pisaura zonaformis Wang,1993的分类地位进行了修订。研究结果表明,马蹄溯蛛Hygropoda hippocrepiforma Wang,1993为长肢溯蛛Hygropoda higenaga(Kishida,1936)的新异名,移带形盗蛛Pisaura zonaformis Wang ,1993到东洋蛛属Polyboea,该属亦为我国新记录属。